Glenmark Pharmaceuticals’ arm, Lotus International enter into exclusive licensing agreement

20 Jan 2022 Evaluate

Glenmark Pharmaceuticals’ Swiss subsidiary -- Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Lotus International Pte a wholly owned subsidiary of Lotus Pharmaceutical (Lotus), for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

Under the terms of the agreement, the company will be responsible for the manufacture and supply of Ryaltris, whereas Lotus will be responsible for commercialization of Ryaltris (subject to receipt of regulatory approvals), in these markets. Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×